We are building a world-class biopharmaceutical company with a dedicated team of management and advisors with therapeutic area expertise in severe pulmonary diseases and respiratory drug development.
John joined Spyryx as CEO in December 2013 with the goal of building the Company into a therapeutic development organization targeting severe lung diseases. This role relies heavily on his prior experience in business and corporate development for small pharmaceutical and biotechnology companies, including considerable focus on rare and orphan diseases. In addition to Spyryx, John has provided leadership to several other biopharmaceutical start-ups, including JUNCTIONRx, a company he founded to pursue orphan drug development. Previously, he spent almost four years as Vice President, Corporate Development at Synageva BioPharma (acquired by Alexion Pharmaceuticals), a biotechnology company focused on protein therapeutics for rare diseases, which he helped to take public via a reverse merger with Trimeris. Prior to joining Synageva, John was the Vice President, Business Development for Javelin Pharmaceuticals, a clinical and commercial stage specialty pharmaceutical company developing treatments for acute pain. Earlier in his career John held positions of increasing responsibility in licensing and business development, marketing, and sales with Eurand Pharma, Sarnoff Corporation, Amersham Pharmacia Biotech and BioWhittaker. John received his Bachelors degree in Biological Sciences from Clemson University and his Masters degree in Technology Management from the Wharton School of Business at the University of Pennsylvania.
Alistair joined Spyryx in 2016 to lead the Company's clinical development operations, medical affairs and regulatory strategy. He brings to the Company nearly 35 years of global drug development experience, including work across all phases of development with both small molecules and biologics. He has been personally responsible for over 30 INDs/CTAs and had key roles in the filing of nine successful marketing applications with regulatory agencies worldwide. A large majority of this work has been focused in the respiratory field, developing products for nasal allergy, rhinitis, asthma, COPD, and pneumonia. Additionally, Alistair’s family has a connection to Cystic Fibrosis that fuels his passion to make a meaningful impact for these patients as well.
Prior to joining Spyryx, Alistair was the Global Head of Clinical Development, Respiratory Medicine and Biotherapeutics at Sunovion Pharmaceuticals, where he was responsible for all clinical development activities, including the recent NDA filing for SUN-101 in COPD which he led from Phase 2 onward, and the support of clinical expansion for Sunovion's approved products in multiple therapeutic areas. Before Sunovion, Alistair was Senior Director, Clinical Research at Cubist Pharmaceuticals, leading the clinical research function for development programs in infectious disease and cardiovascular surgery, as well as leading the clinical support for marketed products. Alistair’s earlier clinical development and medical affairs experience included positions in both the US and Europe at Avant Immunotherapeutics, Astra USA, Hoffmann-LaRoche, and Glaxo.
Alistair earned his MD from the Royal London Hospital Medical College and his MFPM from the Royal College of Physicians. He is a member of the American Thoracic Society and former vice president of the American Academy of Pharmaceutical Physicians.
Timm joined Spyryx in 2015 to lead inhaled product development, device selection and manufacturing and supply for Spyryx’s product candidates. He came to the Company from GlaxoSmithKline where he was most recently Director of Advanced Manufacturing Technology, leading innovation in the areas of aerosol release testing, technology enhanced manufacturing strategies, electronic inhaler and particle engineering technologies. Earlier in his GSK career he contributed to late-stage development of GSK’s current asthma and COPD products. Prior to GSK, Timm was co-founder of Oriel Therapeutics, an inhaler technology company built around device designs he developed during his graduate research. Oriel was subsequently acquired by Sandoz Pharmaceuticals.
Timm earned his PhD in Biomedical Engineering from the University of North Carolina-Chapel Hill and has degrees in Physics from North Carolina State University and Davidson College. He is an inventor on 10 issued patents on inhalers and powder filling systems and has 25 publications, book chapters and international presentations relating to aerosol drug delivery, inhaler design, powder filling, powder flow, formulation and product characterization.
Rob is the scientific founder of Spyryx Biosciences and has been a board director since the Company was formed in 2013. He is an Associate Professor in UNC-Chapel Hill's Department of Cell Biology and Physiology and a member of the Lineberger Cancer Center and the Cystic Fibrosis Center. He is also the Director of UNC’s NIH/FDA-funded Tobacco Center of Regulatory Science and Co-Director of UNC’s Cystic Fibrosis Program Project Grant. Rob currently serves on multiple advisory and steering committees for the FDA and for the Cystic Fibrosis Foundation. His research interests have centered around studying the role of ion channels in relation to the abnormal fluid hydration commonly seen in lung diseases such as CF, COPD, and asthma. He trained at Newcastle University, UK where he performed CFTR electrophysiology and at UNC-Chapel Hill where he studied epithelial transport and CF pathogenesis. Rob has published over 50 papers and it is his work on how defective CFTR function leads to dehydrated mucus and chronic lung disease that led to the discoveries upon which Spyryx was founded. Another of Rob's contributions to the field includes the co-development of the confocal-based airway surface liquid (ASL) height assay that is now being widely adopted to study CF and COPD.
Scientific Founder & Chair, SAB - Spyryx Biosciences
President & Chief Executive Officer - Spyryx Biosciences